Timothy Philips
YOU?
Author Swipe
View article: 2787. Carbapenem Versus Non-Carbapenem Based Therapy for Blood Stream Infection Caused by <i>Serratia Marcescen</i>s: A Multicenter Retrospective Cohort Study
2787. Carbapenem Versus Non-Carbapenem Based Therapy for Blood Stream Infection Caused by <i>Serratia Marcescen</i>s: A Multicenter Retrospective Cohort Study Open
Background Carbapenems were commonly prescribed for "SPACE" organisms. Recent IDSA guidance recommends narrower-spectrum beta-lactams for lower AmpC-induction risk bacteria, like Serratia. Prior studies focused on other Enterobacterales, w…
View article: 2788. Cefepime or Carbapenem Definitive Therapy Versus Other Antibiotics for Blood Stream Infections Caused by Non-ESBL-Producing <i>Serratia Marcescens</i>: A Multicenter Retrospective Cohort Study
2788. Cefepime or Carbapenem Definitive Therapy Versus Other Antibiotics for Blood Stream Infections Caused by Non-ESBL-Producing <i>Serratia Marcescens</i>: A Multicenter Retrospective Cohort Study Open
Background Serratia Marcescens causes serious infections. Carbapenems were preferred due to fear of inducible AmpC resistance. IDSA guidance now recommends ceftriaxone, and in high-burden cases, cefepime. Evidence on Serratia bacteremia tr…